PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY Russian patent published in 2019 - IPC C07D471/04 A61K31/437 A61P29/00 A61P25/00 A61P25/28 A61P27/02 A61P35/00 A61P37/06 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to substituted pyrazolo[1,5-a]pyridine derivatives of formula (IIB) or pharmaceutically acceptable salts thereof, in which E denotes -CH₂-; Q is -CH₂-; Z is hydrogen or methyl; V denotes CR²² or N; R¹² denotes hydrogen; R¹⁵ denotes a difluoromethoxy group; R¹⁶ denotes hydrogen; R²¹ denotes hydroxy (C₁-C_b) alkyl; or R²¹ denotes piperidinyl, piperazinyl or morpholinyl, any of these groups may optionally contain one, two or three substitutes independently selected from a group comprising C₁-C₆-alkyl, C₁-C₆-alkylsulfonyl, oxo group and carboxy group; R²² denotes hydrogen, halogen or C₁-C₆-alkyl; and R²³ denotes hydrogen, C₁-C₆-alkyl, trifluoromethyl or C₁-C₆-alkoxy group. Compounds of formula (IIB) are active modulators of TNFα activity rights and can be used for treating and/or preventing various human diseases, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ophthalmic disorders and oncological disorders

.

EFFECT: most preferably compounds can be used for preparing a drug for treating and/or preventing rheumatoid arthritis or Crohn's disease and in a method of treating or preventing these diseases.

6 cl, 7 ex